SciClone, Schering-Plough unit set Zadaxin settlement

MikeMaynard

WASHINGTON (MarketWatch) -- SciClone Pharmaceuticals Inc.
SCLN, -0.97%
said it will receive $8 million to settle a dispute with a Japanese subsidiary of Schering-Plough Corp.
SGP, -0.06%
concerning clinical trials conducted with Zadaxin, SciClone's lead compound. San Mateo, Calif.-based SciClone said it will keep open the option of pursuing further clinical development in Japan with Zadaxin, which is in the midst of late-stage clinical trials as a treatment of malignant melanoma and hepatitis C. The company's "immediate focus for Zadaxin remains on the pursuit of regulatory approvals in the United States and Europe," said Dr. Ira Lawrence, SciClone's president and chief executive. Shares of SciClone added a penny to close Friday's trading at $3.57.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.